Prosecution Insights
Prosecution Insights
38 pending office actions • 23 art units • 36 examiners • 0 of 38 (0%) have an AI response strategy ready • 44 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 37 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 37 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 23 (61%) |
| §102 only | 3 (8%) |
| §112 only | 2 (5%) |
| No statute on record | 10 (26%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELYAVSKYI, MICHAIL A | 3 | 63.8% | +27.5% |
| GIBBS, TERRA C | 1 | 64.1% | +10.6% |
| BERTOGLIO, VALARIE E | 1 | 64.2% | +29.6% |
| LEE, YIE CHIA | 1 | 72.7% | +43.4% |
| ALAM, DANYAL HASSAN | 1 | 100.0% | +0.0% |
| DARPOLOR, JOSEPHINE KEBBEH | 1 | 61.5% | +41.7% |
| DROUIN, STEVE HOANG | 1 | — | — |
| GROOMS, TIFFANY NICOLE | 1 | 58.8% | +45.3% |
| SUNSHINE, HANNAH LOUISE | 1 | 71.0% | +13.3% |
| BENAVIDES, JENNIFER ANN | 1 | 50.0% | +44.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279581 | MUC16 PROMOTER CONTAINING VIRUS | ALAM, DANYAL HASSAN | 32d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277218 | ANTI-DOMAIN IV EGFR ANTIBODIES AND USES THEREOF | DARPOLOR, JOSEPHINE KEBBEH | 49d overdue |
| 18277367 | TRUNCATED DOMAIN IV EGFR AND USES THEREOF | BELYAVSKYI, MICHAIL A | 28d overdue |
| 17789930 | METHODS OF MAKING AND USING REGULATORY T CELLS AND EFFECTOR T CELLS HAVING CHIMERIC ANTIGEN RECEPTORS TARGETED TO CD6, CD19, AND/OR AN IL-13R FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCERS | BELYAVSKYI, MICHAIL A | 16d overdue |
| 18220070 | PREVENTION OR TREATMENT OF WASTING SYNDROME | GROOMS, TIFFANY NICOLE | 2d overdue |
| 18284413 | CAR T CELL THERAPY AND IFN GAMMA | LEE, YIE CHIA | 9d |
| 18488859 | TREATMENT OF CANAVAN DISEASE | BERTOGLIO, VALARIE E | 21d |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | GIBBS, TERRA C | 29d |
| 18271026 | NATURAL KILLER CELLS ENGINEERED TO REDUCE OR ELIMINATE CBL-B AND USES THEREOF | SUNSHINE, HANNAH LOUISE | 48d |
| Art Unit | Apps |
|---|---|
| 1644 | 4 |
| 1675 | 4 |
| 1642 | 3 |
| 1635 | 2 |
| 1637 | 2 |
| 1647 | 2 |
| 1633 | 2 |
| 1643 | 2 |
| 1638 | 2 |
| 1641 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | GIBBS, TERRA C | 1635 | §103 | Final Rejection | 29d | Pending | May 02, 2024 |
| 18421826 | METHODS FOR MANUFACTURING T CELLS EXPRESSING OF CHIMERIC ANTIGEN RECEPTORS AND OTHER RECEPTORS | BELYAVSKYI, MICHAIL A | 1644 | §103 | Final Rejection | 72d | Pending | Jan 24, 2024 |
| 18488859 | TREATMENT OF CANAVAN DISEASE | BERTOGLIO, VALARIE E | 1632 | Other | Non-Final OA | 21d | Pending | Oct 17, 2023 |
| 18284413 | CAR T CELL THERAPY AND IFN GAMMA | LEE, YIE CHIA | 1642 | §103 | Non-Final OA | 9d | Pending | Sep 27, 2023 |
| 18279581 | MUC16 PROMOTER CONTAINING VIRUS | ALAM, DANYAL HASSAN | 1672 | §103 | Non-Final OA | 32d overdue | Pending | Aug 30, 2023 |
| 18277367 | TRUNCATED DOMAIN IV EGFR AND USES THEREOF | BELYAVSKYI, MICHAIL A | 1644 | §103 | Non-Final OA | 28d overdue | Pending | Aug 15, 2023 |
| 18277218 | ANTI-DOMAIN IV EGFR ANTIBODIES AND USES THEREOF | DARPOLOR, JOSEPHINE KEBBEH | 1642 | Other | Non-Final OA | 49d overdue | Pending | Aug 14, 2023 |
| 18361492 | METHODS OF TREATING A CORONAVIRUS INFECTION | DROUIN, STEVE HOANG | 1627 | §103 | Non-Final OA | 28d | Pending | Jul 28, 2023 |
| 18220070 | PREVENTION OR TREATMENT OF WASTING SYNDROME | GROOMS, TIFFANY NICOLE | 1637 | §103 | Non-Final OA | 2d overdue | Pending | Jul 10, 2023 |
| 18271026 | NATURAL KILLER CELLS ENGINEERED TO REDUCE OR ELIMINATE CBL-B AND USES THEREOF | SUNSHINE, HANNAH LOUISE | 1647 | §103 | Non-Final OA | 48d | Pending | Jul 05, 2023 |
| 18266443 | COMPOSITIONS AND USES OF CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED IMMUNE CELLS | BENAVIDES, JENNIFER ANN | 1675 | §103 | Non-Final OA | 70d | Pending | Jun 09, 2023 |
| 18265544 | COMPOUNDS AND METHODS TO TREAT CYSTIC FIBROSIS | PRONZATI, GINA | 1633 | §103 | Non-Final OA | 12d | Pending | Jun 06, 2023 |
| 18255503 | PREVENTION AND TREATMENT OF GRAFT-VERSUS-HOST DISEASE (GVHD) | CESARE, JOSEPH DAVID | 1675 | §103 | Non-Final OA | 8d overdue | Pending | Jun 01, 2023 |
| 18038423 | COMPOSITIONS AND USES OF PSCA TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS | FAUST, AMBER KATHLEEN | 1643 | Other | Non-Final OA | 42d overdue | Pending | May 23, 2023 |
| 18320106 | COMPOSITION AND METHODS FOR 3D CULTURE OF ISLET CELLS | SMITH, ADAM MICHAEL | 1638 | §103 | Non-Final OA | 86d overdue | Pending | May 18, 2023 |
| 18033980 | NUCLEIC ACIDS, PROTEINS, AND VACCINES OF SARS-COV-2 | GILL, RACHEL B | 1671 | §103 | Non-Final OA | 66d overdue | Pending | Apr 26, 2023 |
| 18033777 | ENGINEERED NK CELLS | HAM, JIEUN | 1643 | Other | Non-Final OA | 56d | Pending | Apr 25, 2023 |
| 18032201 | HYDROPHOBIC DRUGS IN ORGANIC CORE HIGH DENSITY LIPOPROTEIN (HDL) NANOPARTICLES | AL-AWADI, DANAH J | 1615 | Other | Non-Final OA | 66d overdue | Pending | Apr 17, 2023 |
| 18026335 | EX VIVO EXPANSION OF REGULATORY T CELLS FOR SUPPRESSION OF GRAFT VERSUS HOST DISEASE | JUEDES, AMY E | 1644 | §103 | Non-Final OA | 15d | Pending | Mar 14, 2023 |
| 18023536 | NOVEL CELL LINES, METHODS OF PRODUCING NATURAL KILLER CELLS AND USES THEREOF | LUNDE, GRACE HENRY | 1641 | Other | Non-Final OA | 34d | Pending | Feb 27, 2023 |
| 18042434 | LAMP DETECTION OF SARS-COV-2 IN SALIVA FOR THE RAPID DIAGNOSIS OF COVID-19 | SWITZER, JULIET CAROLINE | 1682 | §103 | Non-Final OA | 23d overdue | Pending | Feb 21, 2023 |
| 18017982 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | MARTINEZ, TARA L | 1654 | Other | Non-Final OA | 29d | Pending | Jan 25, 2023 |
| 18017841 | PEPTIDE DESIGN AND GALECTIN-3 INHIBITORS | MACFARLANE, STACEY NEE | 1675 | §102 | Non-Final OA | 36d overdue | Pending | Jan 24, 2023 |
| 18066132 | MULTIVALENT MEDITOPES, MEDITOPE-BINDING ANTIBODIES AND USES THEREOF | DIBRINO, MARIANNE | 1641 | §112 | Non-Final OA | 50d overdue | Pending | Dec 14, 2022 |
| 17976670 | NASAL SWAB | KREMER, MATTHEW | 3791 | §112 | Final Rejection | 3d overdue | Pending | Oct 28, 2022 |
| 17919178 | FLT3-TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS FOR TREATMENT OF FLT3-POSITIVE MALIGNANCIES | REDDIG, PETER J | 1646 | §103 | Final Rejection | 8d overdue | Pending | Oct 14, 2022 |
| 17906467 | MULTIVALENT CHEMOKINE RECEPTOR BINDING COMPLEXES | PATTERSON, SARAH COOPER | 1675 | §103 | Non-Final OA | 37d overdue | Pending | Sep 15, 2022 |
| 17932239 | SYNTHETIC MODIFIED VACCINIA ANKARA (sMVA) BASED CORONAVIRUS VACCINES | QIAN, CELINE X | 1637 | Other | Final Rejection | 217d overdue | Pending | Sep 14, 2022 |
| 17910459 | DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS COMPRISING IL-13 AND CHLOROTOXIN FOR CANCER TREATMENT | HILL, KEVIN KAI | 1638 | §103 | Non-Final OA | 9d overdue | Pending | Sep 09, 2022 |
| 17789930 | METHODS OF MAKING AND USING REGULATORY T CELLS AND EFFECTOR T CELLS HAVING CHIMERIC ANTIGEN RECEPTORS TARGETED TO CD6, CD19, AND/OR AN IL-13R FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCERS | BELYAVSKYI, MICHAIL A | 1644 | Other | Non-Final OA | 16d overdue | Pending | Jun 29, 2022 |
| 17843073 | ACCESS NEEDLE SYSTEMS AND METHODS | LI, JOHN DENNY | 3798 | §103 | Non-Final OA | 29d | Pending | Jun 17, 2022 |
| 17774088 | GENERATION OF CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FROM STEM CELLS AND THERAPEUTIC USES THEREOF | WESTON, ALYSSA G | 1633 | §102 | Final Rejection | 60d overdue | Pending | May 03, 2022 |
| 17632869 | DUAL BISPECIFIC ANTIBODY COMPOUNDS AND USES THEREOF | GURLEY, JAMI MICHELLE | 1647 | §103 | Final Rejection | — | Pending | Feb 04, 2022 |
| 17621909 | PDL1 POSITIVE NK CELL CANCER TREATMENT | LU, CHENG | 1642 | §103 | Final Rejection | 112d overdue | Pending | Dec 22, 2021 |
| 17615695 | APTAMERS AGAINST TRANSFERRIN RECEPTOR | SHIN, DANA H | 1635 | Other | Final Rejection | 93d overdue | Pending | Dec 01, 2021 |
| 17520402 | CHIMERIC ANTIGEN RECEPTORS CONTAINING A CHLOROTOXIN DOMAIN | HINES, JANA A | 1645 | §103 | Non-Final OA | 110d overdue | Pending | Nov 05, 2021 |
| 17184987 | Surgical Gauze | ARBLE, JESSICA R | 3781 | §102 | Final Rejection | 26d | Pending | Feb 25, 2021 |
| 17269229 | OLIGONUCLEOTIDE INHIBITORS OF NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS AND THE USES THEREOF | ZAHORIK, AMANDA MARY | 1636 | §103 | Non-Final OA | 38d overdue | Pending | Feb 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial